<p>阿玛琳公司（NASDAQ:AMRN - 获取免费报告）在四月份的空头头寸显著下降。截至四月十五日，空头头寸总计 629,400 股，较三月三十一日的 11,970,000 股下降了 94.7%。该公司约有 3.1% 的股票被做空。根据 88,700 股的平均交易量，目前的空头比例为 7.1 天。</p>
<h2>分析师升级与降级</h2>
<ul>
<li>三只生物科技股票正在获得动力</li>
</ul>
<p>AMRN 已成为多份分析师报告的主题。StockNews.com 在四月十六日（星期三）的一份研究报告中开始覆盖阿玛琳的股票。他们对该公司给予了 “卖出” 评级。高盛集团在四月十七日（星期四）的研究报告中将阿玛琳的目标价从 20.00 美元下调至 7.00 美元，并对该公司设定了 “卖出” 评级。</p>
<p><strong>查看我们关于 AMRN 的最新股票报告</strong></p>
<h2>阿玛琳股票下跌 6.7%</h2>
<ul>
<li>Ocugen 或阿玛琳是否值得投资的便士股票？</li>
</ul>
<p>NASDAQ:AMRN 的股票在周五交易中下跌了 0.75 美元，达到 10.43 美元。该股票的交易量为 55,645 股，而其平均交易量为 73,755 股。该股票的 50 日简单移动平均为 9.62 美元，200 日简单移动平均为 10.39 美元。阿玛琳的 52 周低点为 7.08 美元，52 周高点为 20.60 美元。该公司的市值为 2.1417 亿美元，市盈率为-115.89，贝塔值为 1.38。</p>
<p>阿玛琳（NASDAQ:AMRN - 获取免费报告）最后一次公布财报是在三月十二日（星期三）。这家生物制药公司报告本季度每股收益为（2.40 美元），低于市场共识预期的（1.20 美元）1.20 美元。阿玛琳的股本回报率为-7.22%，净利润率为-16.33%。该公司本季度的收入为 6231 万美元，而市场共识预期为 3237 万美元。分析师平均预测阿玛琳在当前年度的每股收益为-0.15 美元。</p>
<h2>机构资金流入与流出</h2>
<ul>
<li>阿玛琳在财报发布后是否值得加入你的投资组合？</li>
</ul>
<p>一些大型投资者最近调整了他们对 AMRN 的持股。纽约州共同退休基金在第四季度购买了阿玛琳的新头寸，价值 68,000 美元。Waterfront Wealth Inc.在第四季度将其在阿玛琳的持股增加了 181.4%。Waterfront Wealth Inc.现在拥有 2481766 股这家生物制药公司的股票，价值 1,204,000 美元，此前在该期间又购买了 1,599,956 股。Arkfeld Wealth Strategies L.L.C.在第四季度将其在阿玛琳的持股增加了 52.6%。Arkfeld Wealth Strategies L.L.C.现在拥有 58,000 股这家生物制药公司的股票，价值 30,000 美元，此前在上个季度又购买了 20,000 股。LCM Capital Management Inc 在第四季度将其在阿玛琳的持股增加了 3.1%。LCM Capital Management Inc 现在拥有 838,259 股这家生物制药公司的股票，价值 407,000 美元，此前在该期间又购买了 25,100 股。最后，Stonepine Capital Management LLC 在第四季度收购了阿玛琳的新股份，价值约 55,000 美元。目前 22.25% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于阿玛琳</h2>
<p>（获取免费报告）</p>
<p>阿玛琳公司是一家制药公司，专注于在美国、欧洲国家、加拿大、黎巴嫩和阿拉伯联合酋长国开发和商业化治疗心血管疾病的疗法。该公司提供 VASCEPA，这是一种仅限处方的 omega-3 脂肪酸产品，用于作为饮食的辅助治疗，以降低严重高甘油三酯血症成年患者的甘油三酯水平。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票而非阿玛琳</li>
<li>哪些华尔街分析师最准确？</li>
<li>市场认为 Robinhood 的财报可能会推动股票上涨</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>Churchill Downs 股票：关税担忧是否会抑制德比收益？</li>
<li>股票平均计算器</li>
<li>AT&amp;T：用户增长与回购信号看涨反转</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在阿玛琳吗？</h2>
<p>在考虑阿玛琳之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而阿玛琳并不在名单上。</p>
<p>虽然阿玛琳目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿玛琳

<p>阿玛琳公司（NASDAQ:AMRN）在 4 月 15 日的空头头寸大幅下降，下降了 94.7%，降至 629,400 股。这大约占公司股份的 3.1%。根据 88,700 股的平均交易量，目前的覆盖天数比率为 7.1 天。分析师给出了 “卖出” 评级，高盛将目标股价从 20.00 美元下调至 7.00 美元。阿玛琳的股票下跌了 6.7%，交易价格为 10.43 美元，市值为 2.1417 亿美元，上一季度的每股收益为负 2.40 美元</p>

<p>Amarin Co. plc (NASDAQ:AMRN - Get Free Report) saw a significant decline in short interest in April. As of April 15th, there was short interest totalling 629,400 shares, a decline of 94.7% from the March 31st total of 11,970,000 shares. Approximately 3.1% of the company's stock are short sold. Based on an average trading volume of 88,700 shares, the short-interest ratio is presently 7.1 days.</p>
<div class="lb-trans"><p>阿玛琳公司（NASDAQ:AMRN - 获取免费报告）在四月份的空头头寸显著下降。截至四月十五日，空头头寸总计 629,400 股，较三月三十一日的 11,970,000 股下降了 94.7%。该公司约有 3.1% 的股票被做空。根据 88,700 股的平均交易量，目前的空头比例为 7.1 天。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级与降级</h2>
</div><ul>
<li>3 Biotech Stocks Gaining Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>三只生物科技股票正在获得动力</li>
</ul>
</div><p>AMRN has been the subject of several analyst reports. StockNews.com assumed coverage on shares of Amarin in a research note on Wednesday, April 16th. They issued a &#34;sell&#34; rating for the company. The Goldman Sachs Group reduced their price target on Amarin from $20.00 to $7.00 and set a &#34;sell&#34; rating for the company in a research report on Thursday, April 17th.</p>
<div class="lb-trans"><p>AMRN 已成为多份分析师报告的主题。StockNews.com 在四月十六日（星期三）的一份研究报告中开始覆盖阿玛琳的股票。他们对该公司给予了 “卖出” 评级。高盛集团在四月十七日（星期四）的研究报告中将阿玛琳的目标价从 20.00 美元下调至 7.00 美元，并对该公司设定了 “卖出” 评级。</p>
</div><p><strong>Check Out Our Latest Stock Report on AMRN</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 AMRN 的最新股票报告</strong></p>
</div><h2>Amarin Stock Down 6.7 %</h2>
<div class="lb-trans"><h2>阿玛琳股票下跌 6.7%</h2>
</div><ul>
<li>Are Ocugen or Amarin Good Penny Stocks to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>Ocugen 或阿玛琳是否值得投资的便士股票？</li>
</ul>
</div><p>Shares of NASDAQ:AMRN traded down $0.75 during trading on Friday, reaching $10.43. The stock had a trading volume of 55,645 shares, compared to its average volume of 73,755. The stock has a fifty day simple moving average of $9.62 and a two-hundred day simple moving average of $10.39. Amarin has a 52 week low of $7.08 and a 52 week high of $20.60. The firm has a market capitalization of $214.17 million, a price-to-earnings ratio of -115.89 and a beta of 1.38.</p>
<div class="lb-trans"><p>NASDAQ:AMRN 的股票在周五交易中下跌了 0.75 美元，达到 10.43 美元。该股票的交易量为 55,645 股，而其平均交易量为 73,755 股。该股票的 50 日简单移动平均为 9.62 美元，200 日简单移动平均为 10.39 美元。阿玛琳的 52 周低点为 7.08 美元，52 周高点为 20.60 美元。该公司的市值为 2.1417 亿美元，市盈率为-115.89，贝塔值为 1.38。</p>
</div><p>Amarin (NASDAQ:AMRN - Get Free Report) last announced its earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($1.20) by ($1.20). Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. The firm had revenue of $62.31 million during the quarter, compared to the consensus estimate of $32.37 million. On average, analysts forecast that Amarin will post -0.15 EPS for the current year.</p>
<div class="lb-trans"><p>阿玛琳（NASDAQ:AMRN - 获取免费报告）最后一次公布财报是在三月十二日（星期三）。这家生物制药公司报告本季度每股收益为（2.40 美元），低于市场共识预期的（1.20 美元）1.20 美元。阿玛琳的股本回报率为-7.22%，净利润率为-16.33%。该公司本季度的收入为 6231 万美元，而市场共识预期为 3237 万美元。分析师平均预测阿玛琳在当前年度的每股收益为-0.15 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><ul>
<li>Does Amarin Deserve a Spot in Your Portfolio after Earnings ?</li>
</ul>
<div class="lb-trans"><ul>
<li>阿玛琳在财报发布后是否值得加入你的投资组合？</li>
</ul>
</div><p>A number of large investors have recently modified their holdings of AMRN. New York State Common Retirement Fund bought a new position in Amarin during the fourth quarter worth $68,000. Waterfront Wealth Inc. increased its holdings in shares of Amarin by 181.4% during the 4th quarter. Waterfront Wealth Inc. now owns 2,481,766 shares of the biopharmaceutical company's stock worth $1,204,000 after purchasing an additional 1,599,956 shares during the period. Arkfeld Wealth Strategies L.L.C. raised its position in shares of Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 20,000 shares during the last quarter. LCM Capital Management Inc lifted its stake in shares of Amarin by 3.1% in the fourth quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company's stock valued at $407,000 after buying an additional 25,100 shares during the period. Finally, Stonepine Capital Management LLC acquired a new stake in Amarin during the fourth quarter worth about $55,000. 22.25% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了他们对 AMRN 的持股。纽约州共同退休基金在第四季度购买了阿玛琳的新头寸，价值 68,000 美元。Waterfront Wealth Inc.在第四季度将其在阿玛琳的持股增加了 181.4%。Waterfront Wealth Inc.现在拥有 2481766 股这家生物制药公司的股票，价值 1,204,000 美元，此前在该期间又购买了 1,599,956 股。Arkfeld Wealth Strategies L.L.C.在第四季度将其在阿玛琳的持股增加了 52.6%。Arkfeld Wealth Strategies L.L.C.现在拥有 58,000 股这家生物制药公司的股票，价值 30,000 美元，此前在上个季度又购买了 20,000 股。LCM Capital Management Inc 在第四季度将其在阿玛琳的持股增加了 3.1%。LCM Capital Management Inc 现在拥有 838,259 股这家生物制药公司的股票，价值 407,000 美元，此前在该期间又购买了 25,100 股。最后，Stonepine Capital Management LLC 在第四季度收购了阿玛琳的新股份，价值约 55,000 美元。目前 22.25% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Amarin</h2>
<div class="lb-trans"><h2>关于阿玛琳</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.</p>
<div class="lb-trans"><p>阿玛琳公司是一家制药公司，专注于在美国、欧洲国家、加拿大、黎巴嫩和阿拉伯联合酋长国开发和商业化治疗心血管疾病的疗法。该公司提供 VASCEPA，这是一种仅限处方的 omega-3 脂肪酸产品，用于作为饮食的辅助治疗，以降低严重高甘油三酯血症成年患者的甘油三酯水平。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Amarin</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Markets Think Robinhood Earnings Could Send the Stock Up</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?</li>
<li>Stock Average Calculator</li>
<li>AT&amp;T: Subscriber Growth &amp; Buybacks Signal Bullish Turnaround</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票而非阿玛琳</li>
<li>哪些华尔街分析师最准确？</li>
<li>市场认为 Robinhood 的财报可能会推动股票上涨</li>
<li>如何在 7 个步骤中投资大麻股票</li>
<li>Churchill Downs 股票：关税担忧是否会抑制德比收益？</li>
<li>股票平均计算器</li>
<li>AT&amp;T：用户增长与回购信号看涨反转</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amarin Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在阿玛琳吗？</h2>
</div><p>Before you consider Amarin, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑阿玛琳之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而阿玛琳并不在名单上。</p>
</div><p>While Amarin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿玛琳目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

阿玛琳公司（NASDAQ:AMRN）空头头寸最新情况